相关实验视频

Updated: Jun 18, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

新型抗真菌剂SP-1-39抑制了头部和部状细胞癌

K L Adeleye¹, A R Li¹, Y Xie¹

¹Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA.

Journal of dental research

|August 5, 2024

概括

新型药物SP-1-39在治疗头部和部状细胞癌 (HNSCC) 方面表现有前途. 临床前研究显示,SP-1-39有效抑制HNSCC生长并诱导细胞死亡,其性能优于帕克利塔塞尔.

科学领域:

在瘤学瘤学.
癌症研究癌症研究
药理学药理学是指药理学的学科.

背景情况:

头部和部癌症 (HNC),特别是头部和部状细胞癌 (HNSCC),带来了重大管理挑战.
目前的HNSCC治疗方法 (手术,放射,化疗) 是有限的,特别是在晚期或耐药阶段.
SP-1-39是一种新型的胆固醇结合部位抑制剂 (CBSI),已在各种癌症类型中表现出有效性,并可以克服药物耐药性.

研究的目的:

评估SP-1-39作为HNSCC潜在的新治疗方法的临床前疗效.
评估SP-1-39对HNSCC细胞增殖,细胞亡,迁移和细胞周期的影响.
在HNSCC异种移植模型中确定SP-1-39的体内抗瘤活性和安全性.

主要方法:

使用两个HNSCC细胞系进行体外研究,以评估SP-1-39对增殖,细胞亡,迁移和细胞周期的影响.
在NSG小鼠中使用皮下异种移植小鼠模型 (底特律562) 的体内研究来评估SP-1-39的瘤生长抑制.
在异种移植模型中,SP-1-39与帕克利塔塞尔疗效的比较.

主要成果:

SP-1-39在实验室中证明了HNSCC细胞增殖的强烈抑制,具有低纳米IC50值 (1.42.1nM).
SP-1-39诱导了剂量依赖的亡,抑制了迁移,并导致HNSCC细胞中的G2/M细胞周期停止.
在体内,SP-1-39在异种移植模型中以2.5 mg/kg的剂量显著抑制了原发性瘤生长,没有可观察到的毒性,显示出优于帕克利塔塞尔 (10 mg/kg) 的疗效.

结论:

SP-1-39对HNSCC具有显著的临床前抗癌活性.
在临床前模型中,SP-1-39显示出有利的疗效概况和安全边际.
在HNSCC治疗中,SP-1-39代表了进一步临床开发的有希望的治疗候选者.

关键词:

灭症 (apoptosis) 是一种死亡的过程.细胞循环停止细胞循环停止素结合部位抑制剂发现药物的发现.它们的扩散和扩散.抑制瘤生长抑制瘤生长

更多相关视频

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...